SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Don't Floss, You Lose - (ATRX) To the RESCUE.
ATRX 0.00010000.0%Aug 1 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Arthur Radley who wrote ()1/25/1999 10:26:00 PM
From: george hoffmann  Read Replies (3) of 182
 
I am a dentist in South Carolina and have ben using Atridox since mid October. This product represents a paradigm shift in the treatment of periodontal disease. I have treated well over 100 patients to date and the results are extraordinary.

Atridox was approved in early sept., 1998 as a monotherapy in one of the largest clinical trials to date. It's only competitor, Periochip (Astra) was approved 6 months earliier as an adjunctive therapy to SRP (scaling and root planing). I have used both products in my practice and have found Atridox to be superior in cost, ease of use, and results.

Gordon Christensen, the premier dental "guru" in the United States, has just released a video on Atridox and will highlight Atridox next month in his CRA (Clinical Research Associates) newsletter. The CRA newsletter has a huge circulation both in the US and abroad. Every dental salesman who comes into my office uses CRA evaluations to sell their products. This endorsement will propel the sales of Atridox "off the chart"

Atridox will soon be approved in the UK and is expected to be approved in Germany and the Scandinavian countries in June or July.

This stock is about to explode!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext